Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R
Institute of Brain Research, Medical School, Tübingen, Germany.
J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):763-8. doi: 10.1136/jnnp.67.6.763.
In vitro studies indicate a role of apoptosis regulatory proteins of the BCL-2 family in the resistance of glioblastoma multiforme to irradiation and chemotherapy. To date, no study has compared the expression of these proteins in initial and recurrent tumours. The differences of expression of BCL-2, BCL-X, BAX, and MCL-1 proteins of paired first resection and recurrence glioblastoma specimens were examined.
Immunohistochemistry was performed in 37 cases of glioblastoma multiforme with paraffin embedded tissue from first resections and their recurrences in three treatment groups (15 radiochemotherapy, 15 irradiation, seven untreated). Ten high power fields were evaluated with an arbitrary score (< 5%=1, 5-50%=2, >50%=3), and cumulative scores for each antigen calculated.
In the whole group, we found a significant up regulation of antiapoptotic BCL-2 (median cumulative score of 15 in the primary, 19 at recurrence; p<0.0001 in the Wilcoxon test), BCLX (median scores 20 and 25, respectively, p<0.0001), and MCL-1 (median scores 11 and 14, p=0.0395), and a significant down regulation of proapoptotic BAX (median scores 14 and 11, p<0.0001). In the subgroups, these trends were also found. No association between protein expression and treatment regimen was found, although significant changes were restricted to the subgroups that received adjuvant chemotherapy. No significant correlation with clinical prognosis was detected with the Kaplan-Meier method.
In the development from initial to recurrent glioblastoma multiforme, the BCL-2 family rheostat shifts towards antiapoptotic adjustment in vivo. Importantly, the changes in BCL-2 family protein expression characterised here were also seen in the subgroup of patients who did not receive adjuvant radiotherapy or chemotherapy, suggesting that the changes of BCL-2 family protein expression result not only from radiochemotherapy but also reflect the natural course of disease.
体外研究表明,BCL-2家族的凋亡调节蛋白在多形性胶质母细胞瘤对放疗和化疗的耐药性中起作用。迄今为止,尚无研究比较这些蛋白在原发性和复发性肿瘤中的表达情况。本研究检测了配对的首次切除和复发性胶质母细胞瘤标本中BCL-2、BCL-X、BAX和MCL-1蛋白表达的差异。
对37例多形性胶质母细胞瘤患者进行免疫组化检测,这些患者的石蜡包埋组织来自首次切除标本及其复发标本,分为三个治疗组(15例接受放化疗,15例接受放疗,7例未治疗)。在10个高倍视野下进行评估并给予任意评分(<5%=1分,5%-50%=2分,>50%=3分),计算每种抗原的累积评分。
在整个研究组中,我们发现抗凋亡蛋白BCL-2(原发性肿瘤的中位累积评分为15分,复发时为19分;Wilcoxon检验p<0.0001)、BCL-X(中位评分分别为20分和25分,p<0.0001)和MCL-1(中位评分分别为11分和14分,p=0.0395)显著上调,而促凋亡蛋白BAX显著下调(中位评分分别为14分和11分,p<0.0001)。在各亚组中也发现了这些趋势。虽然显著变化仅限于接受辅助化疗的亚组,但未发现蛋白表达与治疗方案之间存在关联。采用Kaplan-Meier法未检测到与临床预后的显著相关性。
在从原发性到复发性多形性胶质母细胞瘤的发展过程中,BCL-2家族的调节机制在体内向抗凋亡方向转变。重要的是,在未接受辅助放疗或化疗的患者亚组中也观察到了本文所描述的BCL-2家族蛋白表达的变化,这表明BCL-2家族蛋白表达的变化不仅是由放化疗引起的,还反映了疾病的自然进程。